Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 4/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.42 |
| ▸ | BCKDK | O14874 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | OGG1 | O15527 | 1/20 | 0.40 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27544067 | 0.98 | MCL1 (0.56) | MCL1RXFP1BCKDKMAPK1HDAC1 | |
| SCHEMBL4650792 | 0.85 | MCL1 (0.43) | MCL1RXFP1MAPK1HDAC1HDAC8 | |
| SCHEMBL4651926 | 0.78 | ALDH1A1 (0.53) | RXFP1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL8631381 | 0.76 | OGG1 (0.43) | MCL1RXFP1HDAC1HDAC8HDAC6 | |
| SCHEMBL8904180 | 0.75 | CYP2A6 (0.47) | MCL1HDAC1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL15876151 | 0.74 | MCL1 (0.48) | MCL1RXFP1KDM4EKMT2AHPGD | |
| SCHEMBL11328828 | 0.74 | MCL1 (0.48) | MCL1RXFP1ALDH1A1KDM4EMEN1 | |
| SCHEMBL14246796 | 0.74 | MCL1 (0.48) | MCL1RXFP1BCKDKALDH1A1KDM4E | |
| SCHEMBL29911721 | 0.74 | MCL1 (1.00) | MCL1RXFP1BCKDKMAPK1HDAC1 | |
| SCHEMBL444722 | 0.74 | MCL1 (1.00) | MCL1RXFP1BCKDKMAPK1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107325002-B | Method for synthesizing aryl halide by taking aryl carboxylic acid as raw material | 南昌大学 | 2020-03-27 | — | — | CN | disclosed |
| US-9491941-B2 | (Hetero) arylacrylamides for the control of ectoparasites | NOVARTIS TIERGESUNDHEIT AG (CH) | 2016-11-15 | — | — | US | disclosed |
| US-20150320044-A1 | (HETERO) ARYLACRYLAMIDES FOR THE CONTROL OF ECTOPARASITES | ELANCO TIERGESUNDHEIT AG (CH) | 2015-11-12 | — | — | US | disclosed |
| EP-2934133-A1 | (HETERO) ARYLACRYLAMIDES FOR THE CONTROL OF ECTOPARASITES | Novartis Tiergesundheit AG (CH) | 2015-10-28 | — | — | EP | disclosed |
| WO-2014096381-A1 | (HETERO) ARYLACRYLAMIDES FOR THE CONTROL OF ECTOPARASITES | NOVARTIS AG (CH) | 2014-06-26 | — | — | WO | disclosed |
| US-20070043057-A1 | Lonidamine analogs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043057-A1 | Lonidamine analogs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070015771-A1 | Lonidamine analogs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | US | disclosed |
| US-20070015771-A1 | Lonidamine analogs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | US | disclosed |
| WO-2001007431-A2 | BENZOTHIOPHENE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320044-A1 | (HETERO) ARYLACRYLAMIDES FOR THE CONTROL OF ECTOPARASITES | AAAS, TYR, CAT | MCL1 4093/4885RXFP1 3565/4885BCKDK 2844/4885 |
| US-20070015771-A1 | Lonidamine analogs | LONP1, LPXN, QDPR | MCL1 616/4885RXFP1 429/4885BCKDK 1883/4885 |
| US-20070043057-A1 | Lonidamine analogs | LONP1, LPXN, QDPR | MCL1 616/4885RXFP1 429/4885BCKDK 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.